Zacks Small Cap Research has published a new analyst note.
On February 24, 2020, Avivagen, Inc. (VIVXF) announced
positive and statistically significant results from its New
Zealand dairy trial showing that OxC-beta™ has an effect
against subclinical mastitis. There was a 13.9% rate of
resolution of bacterial infection in cows fed feed containing
OxC-beta compared to a 6.9% resolution rate in the group
fed the control feed containing no antibiotics. . . .
Download the full report on Zacks Small Cap: VIVXF: Positive Results from New Zealand
Livestock Dairy Trial…